Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4489)	5/26/2003 9:53:12 PM
From: StockDung	Respond to of 5582

Thank God its a free country so that I can still call people like you a dimwit. God Bless America where even dimwits like Dan can speak their mind outloud .

To: DanZ who wrote (4489)	5/27/2003 11:04:58 AM
From: StockDung	Respond to of 5582

SOME INFORMATION ABOUT CEOCAST WHICH SHOWS THAT THEY ARE NOTHING MORE THAT COMMON SCAMMERS: Analyst Questions Firm's Ties With Investor-Relations Firm By GREGORY ZUCKERMAN Staff Reporter of THE WALL STREET JOURNAL Someone on Wall Street finally is up in arms about overly bullish stock reports. Get this -- he's an analyst. Even as regulators come down on Wall Street firms over their rah-rah research practices, some investor-relations firms and stock-promotion companies are raking in fees and accepting shares to churn out enthusiastic reports aimed at small investors. At least one securities firm is causing a fuss about it, and in the process focusing an unflattering spotlight on one of the hottest young companies in the world of health-care services, Philadelphia-based eResearch Technology Inc. On Monday, James Kumpel, an analyst at brokerage firm Raymond James & Associates, Inc., lowered his rating on eResearch -- which provides electrocardiogram analysis for clinical trials, among other things -- to "market perform" from "outperform." The chief reason: eResearch last year hired an online investor-relations company, CEOcast Inc., that touts its clients to investors. One example from a CEOcast newsletter late last year: "We think that even a 50% move [of eResearch shares] on Tuesday would not be out of the question." Adding to Mr. Kumpel's concern is that CEOcast has become a major shareholder of eResearch. "We are uncomfortable with the arrangement with CEOcast as [eResearch] has, at a minimum, tolerated its IR firm's promotional tendencies," Mr. Kumpel said in his report. "CEOcast has engaged in ... promotional activity designed to goose demand." While eResearch has sharply boosted its earnings-per-share estimates for the year, the analyst notes that its shares have enjoyed an even-more breathtaking run -- they doubled from year end through May 5, to $33.49 from $16.75. (In 4 p.m. Nasdaq Stock Market trading Thursday, eResearch was down 22 cents at $33.33.) People familiar with the situation say at least one eResearch executive contacted a Raymond James official to complain about Mr. Kumpel's negative report. But Wednesday morning, as news of Mr. Kumpel's criticism circulated and eResearch shares began to weaken, the company announced it would no longer employ CEOcast. Mr. Kumpel so far isn't changing his recommendation, despite a generally bullish view on the company's prospects. Instead, he is concerned about the judgment of eResearch's management to hire CEOcast in the first place. For its part, eResearch sees it differently. "CEOcast has done an outstanding job in expanding the awareness of the company in the investment community," eResearch President and Chief Executive Joe Esposito said in a news release announcing the end of CEOcast's employment. "Recently, however, certain investors and analysts have expressed concerns about CEOcast's position as a significant stockholder. Since CEOcast was unwilling to sell the shares that it has purchased, we felt that this move was in the best interest of all stockholders." CEOcast defends its tactics, and points out that it hasn't sold its eResearch shares despite their climb. "We aren't promoters. We never say anything that isn't true. We relay accurate information," said Ken Sgro, president of CEOCast. "We're a New Age investor-relations firm. That's where the confusion is -- we're the next generation." CEOcast provides original and syndicated broadcast interviews of chief executives read by more than 20,000 portfolio managers, company executives say. Its stock recommendations are included in an online newsletter distributed to 1.6 million investors, according to the executives. These figures couldn't be verified. Most of the firm's clients are among the smallest of the publicly traded companies, though LendingTree Inc. and Evergreen Resources Inc. are larger. CEOcast said it always receives restricted shares in its clients and holds them for at least one year. It also is paid for its services, which include investor relations and mentions in its newsletters. CEOcast owns about 183,000 of eResearch's 10.9 million shares outstanding, most of which were purchased on the open market; the company also has been compensated by eResearch with 12,000 warrants that were exercised at $13.40 a share. CEOcast made clear in its reports that it is a major shareholder in eResearch. (eResearch Technology isn't related to equity-research firm eResearch.) Since eResearch began to work more closely with CEOcast in October of last year, the company has exhorted investors to buy the stock and made predictions of boffo earnings, some of which have been borne out. The strategy worked: Shares of eResearch have soared about 200% since October. Raymond James's Mr. Kumpel says his concern is that CEOcast went beyond "a factual representation of the company's own outlook" to, in effect, promote expectations so high that they "could set up an unforeseen disappointment down the road." In December of last year, according to Mr. Kumpel's report, CEOcast said: "We strongly encourage investors to purchase the stock as early as possible in the morning." It also wrote: "Normally, we are not prone to hyperbole. However we believe we have identified an extraordinary situation for investors to make money." Other times, CEOcast compared the ever-rising price/earnings trading multiple of the $300 million market-cap company to other pricey stocks, such as eBay Inc., Microsoft Corp. and Dell Computer Corp., and even a company that produces organic milk. According to Mr. Kumpel, CEOcast at times seemed to be previewing future eResearch news releases. In its Dec. 2 newsletter, released after the market closed, CEOcast told investors that "the company will issue a major announcement" the next day. The following morning, eResearch announced an initiative to combat short sellers, investors who had placed bearish bets on the stock in the belief it was overvalued. (More than five million of the company's shares remain shorted by investors.) A CEOcast executive said the company had no access to news releases ahead of time. "We are just suggesting [that investors buy shares], we do not recommend stocks the way broker-dealers do," says CEOcast's Mr. Sgro. He pointed out that CEOcast was cautious earlier this year about two clients after executives at the companies ran into trouble with the law or with regulators. "We work hard not to be a pump-and-dump firm and don't act that way," he said. Mr. Kumpel says he only recently became aware of eResearch's association with CEOcast. His downgrade on Monday of the shares is actually his second in the past month; he cited the company's high stock price in the earlier move. He says eResearch has made the right decision cutting ties with CEOcast. "I'm not accusing eResearch of anything other than tolerating this unseemly IR tactic."

To: DanZ who wrote (4489)	5/27/2003 11:04:59 AM
From: StockDung	Respond to of 5582

SOME INFORMATION ABOUT CEOCAST WHICH SHOWS THAT THEY ARE NOTHING MORE THAT COMMON SCAMMERS: Analyst Questions Firm's Ties With Investor-Relations Firm By GREGORY ZUCKERMAN Staff Reporter of THE WALL STREET JOURNAL Someone on Wall Street finally is up in arms about overly bullish stock reports. Get this -- he's an analyst. Even as regulators come down on Wall Street firms over their rah-rah research practices, some investor-relations firms and stock-promotion companies are raking in fees and accepting shares to churn out enthusiastic reports aimed at small investors. At least one securities firm is causing a fuss about it, and in the process focusing an unflattering spotlight on one of the hottest young companies in the world of health-care services, Philadelphia-based eResearch Technology Inc. On Monday, James Kumpel, an analyst at brokerage firm Raymond James & Associates, Inc., lowered his rating on eResearch -- which provides electrocardiogram analysis for clinical trials, among other things -- to "market perform" from "outperform." The chief reason: eResearch last year hired an online investor-relations company, CEOcast Inc., that touts its clients to investors. One example from a CEOcast newsletter late last year: "We think that even a 50% move [of eResearch shares] on Tuesday would not be out of the question." Adding to Mr. Kumpel's concern is that CEOcast has become a major shareholder of eResearch. "We are uncomfortable with the arrangement with CEOcast as [eResearch] has, at a minimum, tolerated its IR firm's promotional tendencies," Mr. Kumpel said in his report. "CEOcast has engaged in ... promotional activity designed to goose demand." While eResearch has sharply boosted its earnings-per-share estimates for the year, the analyst notes that its shares have enjoyed an even-more breathtaking run -- they doubled from year end through May 5, to $33.49 from $16.75. (In 4 p.m. Nasdaq Stock Market trading Thursday, eResearch was down 22 cents at $33.33.) People familiar with the situation say at least one eResearch executive contacted a Raymond James official to complain about Mr. Kumpel's negative report. But Wednesday morning, as news of Mr. Kumpel's criticism circulated and eResearch shares began to weaken, the company announced it would no longer employ CEOcast. Mr. Kumpel so far isn't changing his recommendation, despite a generally bullish view on the company's prospects. Instead, he is concerned about the judgment of eResearch's management to hire CEOcast in the first place. For its part, eResearch sees it differently. "CEOcast has done an outstanding job in expanding the awareness of the company in the investment community," eResearch President and Chief Executive Joe Esposito said in a news release announcing the end of CEOcast's employment. "Recently, however, certain investors and analysts have expressed concerns about CEOcast's position as a significant stockholder. Since CEOcast was unwilling to sell the shares that it has purchased, we felt that this move was in the best interest of all stockholders." CEOcast defends its tactics, and points out that it hasn't sold its eResearch shares despite their climb. "We aren't promoters. We never say anything that isn't true. We relay accurate information," said Ken Sgro, president of CEOCast. "We're a New Age investor-relations firm. That's where the confusion is -- we're the next generation." CEOcast provides original and syndicated broadcast interviews of chief executives read by more than 20,000 portfolio managers, company executives say. Its stock recommendations are included in an online newsletter distributed to 1.6 million investors, according to the executives. These figures couldn't be verified. Most of the firm's clients are among the smallest of the publicly traded companies, though LendingTree Inc. and Evergreen Resources Inc. are larger. CEOcast said it always receives restricted shares in its clients and holds them for at least one year. It also is paid for its services, which include investor relations and mentions in its newsletters. CEOcast owns about 183,000 of eResearch's 10.9 million shares outstanding, most of which were purchased on the open market; the company also has been compensated by eResearch with 12,000 warrants that were exercised at $13.40 a share. CEOcast made clear in its reports that it is a major shareholder in eResearch. (eResearch Technology isn't related to equity-research firm eResearch.) Since eResearch began to work more closely with CEOcast in October of last year, the company has exhorted investors to buy the stock and made predictions of boffo earnings, some of which have been borne out. The strategy worked: Shares of eResearch have soared about 200% since October. Raymond James's Mr. Kumpel says his concern is that CEOcast went beyond "a factual representation of the company's own outlook" to, in effect, promote expectations so high that they "could set up an unforeseen disappointment down the road." In December of last year, according to Mr. Kumpel's report, CEOcast said: "We strongly encourage investors to purchase the stock as early as possible in the morning." It also wrote: "Normally, we are not prone to hyperbole. However we believe we have identified an extraordinary situation for investors to make money." Other times, CEOcast compared the ever-rising price/earnings trading multiple of the $300 million market-cap company to other pricey stocks, such as eBay Inc., Microsoft Corp. and Dell Computer Corp., and even a company that produces organic milk. According to Mr. Kumpel, CEOcast at times seemed to be previewing future eResearch news releases. In its Dec. 2 newsletter, released after the market closed, CEOcast told investors that "the company will issue a major announcement" the next day. The following morning, eResearch announced an initiative to combat short sellers, investors who had placed bearish bets on the stock in the belief it was overvalued. (More than five million of the company's shares remain shorted by investors.) A CEOcast executive said the company had no access to news releases ahead of time. "We are just suggesting [that investors buy shares], we do not recommend stocks the way broker-dealers do," says CEOcast's Mr. Sgro. He pointed out that CEOcast was cautious earlier this year about two clients after executives at the companies ran into trouble with the law or with regulators. "We work hard not to be a pump-and-dump firm and don't act that way," he said. Mr. Kumpel says he only recently became aware of eResearch's association with CEOcast. His downgrade on Monday of the shares is actually his second in the past month; he cited the company's high stock price in the earlier move. He says eResearch has made the right decision cutting ties with CEOcast. "I'm not accusing eResearch of anything other than tolerating this unseemly IR tactic."

To: DanZ who wrote (4489)	5/28/2003 11:43:54 AM
From: StockDung	Respond to of 5582

BOILER ROOM TERMINOLOGY ABC - Stands for the motto "Always Be Closing," from David Mamet´s Glengarry Glen Ross, a bible of bad behavior for the boiler room set COLD CALL - A sales call to a customer who does not know you or your product; the initial pitch to reel the customer in IPO - Stands for initial public offering; a company´s first offering of stock to the public, often followed by a rapid rise in price in the case of a "hot" stock NASD - The National Association of Securities Dealers, the self-regulation body of the securities industry, which develops trading rules and conducts reviews of members´ activities OPENER - Usually a junior broker or trainee who "opens" the customer with a cold call, before a senior broker comes in for the hard-sell close PIKER - A coward, a chicken, a spoil sport - in the boiler room, it refers to a customer who commits to a buy but then doesn´t send a check PITCH THE BITCH - sell stock to women, a boiler room no-no RIP - The broker´s commission for making a stock trade SEC - Securities Exchange Commission, federal agency that regulates the securities industry SERIES SEVEN - a standardized course of study that certifies a person to become a stockbroker WHALE - A customer with a vast net income WOOD - A cold call that gets no results for the senior broker

To: DanZ who wrote (4489)	5/28/2003 10:00:53 PM
From: StockDung	Respond to of 5582

newline.com

To: DanZ who wrote (4489)	5/29/2003 4:20:42 PM
From: StockDung	Respond to of 5582

ANY NEWS ON MTXX PURCHASING THE REPORT TO SEND OUT TO SHAREHOLDERS? THAT IS HOW DAVE IS PAID.. ACCORDING TO HIS WEB SITE. HOW COME WHEN JONATHAN LEBED PUT OUT A REPORT ON MTXX WHY DID NOT THE COMPANY PUT OUT A PRESS RELEASE ABOUT ANALYST COVERAGE? AFTER ALL JONATHAN HAD A "STRONG BUY" ON THE STOCK MTXX:US Matrixx Initiatives Inc More on MTXX:US NewsDetailed QuoteCharts Matrixx Initiatives, Inc. Announces Analyst Coverage; Edgewater Research Partners Initiates Coverage PHOENIX, May 12 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), developer and distributor of the expanded line of Zicam(R) products, today announced that Edgewater Research Partners LLC has initiated coverage of the company. David Lavigne, partner and analyst for Edgewater, wrote the independent report. "Matrixx has just completed a very successful year and first quarter, and we're gratified that the financial market is taking note of our performance," said Carl Johnson, president and chief executive officer. "As we continue to launch new products and grow revenues, we look forward to building increased presence among the analyst community." The Edgewater report comes just one week after Matrixx announced its third consecutive profitable quarter and the introduction of three new products at the Company's 2003 Annual Shareholders Meeting held on April 30. The new additions complement the current line of Zicam Cold Remedy products. All three products, Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts and Zicam Oral Mist, utilize quick-dissolving oral delivery systems, which are designed to appeal to consumers who prefer not to use nasal applications. Each of the three products contains clinically proven active ingredients that actually shorten the duration and severity of the common cold. All products are expected to be available for the 2003-2004 cold season. Matrixx Initiatives, Inc. did not pay Edgewater Research Partners LLC in any form for the initiation and writing of the independent report, and assumes no responsibility for the content or opinions represented in it. About Matrixx Initiatives, Inc. Matrixx Initiatives, Inc. is engaged in the development, manufacture and marketing of innovative drug delivery systems for over-the-counter (OTC) pharmaceuticals. Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells Zicam(R) Cold Remedy nasal gel, a patented, homeopathic remedy that has been clinically proven to significantly reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT - Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce significantly the duration of the common cold. The company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Allergy Relief nasal gel, a homeopathic remedy designed to provide relief to allergy sufferers; Zicam Cold Remedy Swabs; Zicam Kids Size Cold Remedy Swabs; Zicam Extreme Congestion Relief; Zicam Sinus Relief; and Zicam Nasal Moisturizer. For more information regarding Matrixx products, go to www.zicam.com. To find out more about Matrixx Initiatives, Inc. (NASDAQ:MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, chief financial officer, 602-387-5353, whemelt@matrixxinc.com, or Lynn Romero, investor relations, at 602-387-5353, lromero@matrixxinc.com. Matrixx is located at 2375 East Camelback Road, Suite 500, Phoenix, Arizona 85016. Matrixx Initiatives, Inc. Forward Looking Statement Disclaimer: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to expand the Zicam product line and to have its new products available for the 2003/2004 cold season. These forward-looking statements are based on the Company's expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Some factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, difficulties and delays in introducing, manufacturing and marketing the Company's new products, the failure of required stability studies for the new products, lack of market acceptance for the new products and unforeseen expenses incurred in connection with the production and launch of the new products. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Annual Report on Form 10-K filed pursuant to the Securities Exchange Act of 1934. SOURCE Matrixx Initiatives, Inc. -0- 05/12/2003 /CONTACT: William Hemelt, chief financial officer, +1-602-387-5353, whemelt@matrixxinc.com, or Lynn Romero, investor relations, +1-602-387-5353, lromero@matrixxinc.com, both of Matrixx Initiatives/ /Web site: matrixxinc.com / (MTXX) CO: Matrixx Initiatives, Inc.; Edgewater Research Partners LLC; Zicam, LLC ST: Arizona IN: MTC HEA SU: RTG -0- May/12/2003 18:56 GMT Last Updated: May 12, 2003 14:56 EDT ================================ JONATHAN LEBED RATES MTXX "STRONG BUY" Yahoo! Message Boards: MTXX Add to My Yahoo \| Next > [ First \| Last \| Msg List ] Msg #: Reply Post Recommend this Post Ignore this User \| Report Abuse MTXX rated strong buy by: cbobby70 Long-Term Sentiment: Strong Buy 02/03/03 05:05 pm Msg: 78076 of 78102 New research report today by Jonathan Lebed: www. Lebed . biz

To: DanZ who wrote (4489)	5/29/2003 4:34:05 PM
From: StockDung	Respond to of 5582

MTXX ANALYST, NOT DAN BTW forbes.com

To: DanZ who wrote (4489)	5/29/2003 4:47:59 PM
From: StockDung	Respond to of 5582

MTXX, ADD TO CART edgewaterresearch.com HA HA HA HO HO HO HE HE HE HOW ABOUT THAT DISCLAIMER?

To: DanZ who wrote (4489)	5/29/2003 4:49:26 PM
From: StockDung	Respond to of 5582

CAN YOU NAME THE SCHNEIDER SECURITIES STOCKS? edgewaterresearch.com

To: DanZ who wrote (4489)	5/29/2003 4:56:03 PM
From: StockDung	Respond to of 5582

THEY MUST HAVE THOUGHT IT SUCKED SINCE MTXX HAS BOUGHT ZERO AS OF 05/09/03 Issuer Purchase Disclosure As of 05-09-03, Edgewater Research Partners LLC has received 0 annual "all services" subscriptions ($395 each) from MTXX employees and/or Directors. In addition, MTXX purchased 0 individual "MTXX Initial Coverage" research reports at $30 each.

To: DanZ who wrote (4489)	5/29/2003 4:59:24 PM
From: StockDung	Respond to of 5582

yes, i'd like 6,270 dollars worth please..... Issuer Purchase Disclosure To date, EdgeWater Research Partners LLC has received 6 annual "all services" subscriptions ($395 each) from employees and/or directors of AuthentiDate Holdings Corp. ("ADAT") In addition, ADAT has purchased 130 copies of the "ADAT Initial Coverage" research reports at $30 each.

To: DanZ who wrote (4489)	5/29/2003 5:23:18 PM
From: StockDung	Respond to of 5582

SIX GRANDS WORTH RIGHT OUT OF THE DONNER CORP BOOK OF LOVE. Issuer Purchase Disclosure To Date, EdgeWater Research Partners LLC has received 0 annual "all services" subscriptions ($395 each) from employees and/or directors of DISK. In addition, DISK and or its representatives have purchased 0 copies of the "DISK Initial Coverage" research reports at $30 each. On approximately 01-28-03, Lighthouse Capital Ltd., the company's Investor Relations representative purchased 200 "DISK Initial Coverage Research" reports for $30 each.

To: DanZ who wrote (4489)	5/29/2003 5:26:05 PM
From: StockDung	Respond to of 5582

SEVEN THOUSAND ONE HUNDRED AND SIXTY DOLLARS WORTH. SO FAR......... Issuer Purchase Disclosure As of 11-01-02, Edgewater Research Partners LLC has received 10 annual "all services" subscriptions ($395 each) from FDCC employees and/or Directors. In addition, FDCC purchased 100 individual "FDCC Initial Coverage" research reports at $30 each. The company also purchased 30 copies of the 12-31-02 Fiscal 2002 Earnings Update at $7 each. There have been no additional purchases since that time.

To: DanZ who wrote (4489)	5/29/2003 5:28:14 PM
From: StockDung	Respond to of 5582

$2255 WORTH Issuer Purchase Disclosure To Date, EdgeWater Research Partners LLC has received 1 annual "all services" subscriptions ($395 each) from employees and/or directors of Clarion Technologies, Inc. ("CLAR"). In addition, CLAR has purchased 62 copies of the CLAR "Initial Coverage" research reports at $30 each.

To: DanZ who wrote (4489)	5/30/2003 12:01:50 PM
From: StockDung	Respond to of 5582

Paulson now making market in MTXX

To: DanZ who wrote (4489)	5/30/2003 5:30:19 PM
From: StockDung	Respond to of 5582

U.S. Judge Jails Ex-Broker Who Helped Authorities, Then Author May 30 (Bloomberg) -- A former stockbroker who helped authorities investigate organized crime on Wall Street was jailed after prosecutors said his life was in danger because he is featured in a new book about stock fraud. Louis Pasciuto worked at ``chop shops'' that sell small company stocks at inflated prices to investors. Pasciuto pleaded guilty in 1999 to stock fraud and was free on bail. As authorities probed dozens of small brokerages, Pasciuto secretly taped conversations with reputed members of organized crime. His undercover work led to at least 20 arrests, his lawyer said. Authorities didn't know he was also talking to Business Week writer Gary Weiss. In April, after the FBI learned that Weiss had turned the interviews into a book, Manhattan prosecutors said Pasciuto was at risk and moved to jail him. U.S. District Judge Richard Casey today revoked Pasciuto's bail, turning aside lawyer Robert Baum's claim that prosecutors cited safety as a ``pretext'' for their anger. ``What's prompted the government's motion is the publicity surrounding the book,'' Baum told Casey. ``The book came out, and suddenly he's got a safety issue.'' Weiss, author of ``Born to Steal: When the Mafia Hit Wall Street,'' said prosecutors wanted to ``punish Pasciuto for talking to me.'' The Authors Guild has called the government's move a ``serious threat to First Amendment freedoms.'' `Hornet's Nest' Prosecutors deny having an improper motive and say they fear Pasciuto ``stirred up a potential hornet's nest of interest.'' He's ``at risk of harm from friends and associates of the people against whom he had cooperated,'' Assistant U.S. Attorney David Esseks said in court papers. Prosecutors had planned to seek Pasciuto's jailing earlier this month. They relented after reaching a deal with the Staten Island, New York, man that would have sent him to the witness protection program. After Pasciuto learned the details of the program, he backed out of the deal, and prosecutors asked Casey to imprison him. Pasciuto will be sentenced on Aug. 29. He faces up to 10 years in prison, although Baum will seek a lesser sentence because of his cooperation. Business Week is owned by The McGraw-Hill Companies Inc., a New York-based media and publishing company. --David Glovin in U.S. District Court in New York (1) (212) 732- 9245, or at dglovin@bloomberg.net, through the New York newsroom (212) 732-9245. Editor: Rubin.

To: DanZ who wrote (4489)	5/31/2003 3:52:14 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

Gum Tech International Inc "(collectively referred to as the "Manipulated Securities")." This massive fraud focused on the Manipulated Securities, which included, but were not limited to: Advanced Surgical Inc.; Advanced Voice Technologies, Inc.; Applewoods Inc.; Apogee Robotics, Inc.; Aquanatural Pharmaceuticals Corp.; Ariad Pharmaceuticals Corp.; BioSepra, Inc.; Bristol Technology Systems, Inc.; Chemex Pharmaceuticals Inc.; Children's Wonderland, Inc.; Com/Tech Communication Technologies Inc.; Cypros Pharmaceuticals Corp.; Dollar Time Group, Inc.; DNA Plant Technology Inc.; Ecogen, Inc.; Embryo Development Corporation; Envirogen Corp.; Envro, Inc.; Eastco Industrial Safety, Co.; First Team Sports Inc.; Genemedicine, Inc.; Globus Group, Inc.; Guilford Pharmaceuticals Inc.; Gum Tech International Inc.; Hauppauge Digital Inc.; Help At Home Inc.; HemaSure, Inc.; ICOS Corp.; IFS International Inc.; Innovir Laboratories, Inc.; Intelligent Surgical Lasers, Inc.; Iatros Health Network Inc.; Krantor, Corp.; Kushner- Locke, Company; Kitchen Bazaar, Inc.; LaJolla Pharmaceutical Co.; Lasergate Systems, Inc.; Liposome Technology Inc.; LXR Biotechnology Corp.; ML Direct Inc.; Microprobe Corp.; Ministor Peripherals, Inc.; Neoprobe Corp.; NeoRx Corp.; Neurogen Corp.; New Vision Technology Corp.; Nu-tech Bio-Med Inc.; Pacific Animation Imaging Corp., later known as Strategic Solutions Group; Paperclip Imaging Software Inc.; Paramark Enterprises, Inc.; Symbollin, Inc.; Pharmos Corp.; Procept Inc.; Retrospettvia Inc.; Texas Biotechnology Corp.; Universal Automotive Industries, Inc.; Voxtel Advanced Mammography Systems Inc.; Videolan Technologies, Inc.; XeChem International, Inc.; and Xybernaut Corporation (collectively referred to as the "Manipulated Securities"). securities.stanford.edu